Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, ant… Read more
Kilitch Drugs (India) Limited - Asset Resilience Ratio
Kilitch Drugs (India) Limited (KILITCH) has an Asset Resilience Ratio of 21.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Kilitch Drugs (India) Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Kilitch Drugs (India) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹330.90 Million | 8.3% |
| Short-term Investments | ₹539.23 Million | 13.53% |
| Total Liquid Assets | ₹870.13 Million | 21.83% |
Asset Resilience Insights
- Good Liquidity Position: Kilitch Drugs (India) Limited maintains a healthy 21.83% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kilitch Drugs (India) Limited Industry Peers by Asset Resilience Ratio
Compare Kilitch Drugs (India) Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Kilitch Drugs (India) Limited (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Kilitch Drugs (India) Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 16.77% | ₹524.66 Million | ₹3.13 Billion | -8.51pp |
| 2024-03-31 | 25.28% | ₹606.88 Million | ₹2.40 Billion | +7.30pp |
| 2023-03-31 | 17.98% | ₹394.65 Million | ₹2.20 Billion | -4.53pp |
| 2022-03-31 | 22.51% | ₹472.34 Million | ₹2.10 Billion | +4.59pp |
| 2021-03-31 | 17.92% | ₹364.00 Million | ₹2.03 Billion | -1.56pp |
| 2020-03-31 | 19.47% | ₹278.10 Million | ₹1.43 Billion | -0.31pp |
| 2019-03-31 | 19.78% | ₹284.16 Million | ₹1.44 Billion | -7.69pp |
| 2018-03-31 | 27.47% | ₹350.66 Million | ₹1.28 Billion | +2.37pp |
| 2017-03-31 | 25.09% | ₹283.30 Million | ₹1.13 Billion | +5.28pp |
| 2016-03-31 | 19.82% | ₹231.21 Million | ₹1.17 Billion | +0.35pp |
| 2015-03-31 | 19.47% | ₹246.69 Million | ₹1.27 Billion | -10.88pp |
| 2014-03-31 | 30.34% | ₹391.63 Million | ₹1.29 Billion | -48.77pp |
| 2013-03-31 | 79.11% | ₹1.08 Billion | ₹1.37 Billion | +1.34pp |
| 2012-03-31 | 77.77% | ₹1.38 Billion | ₹1.77 Billion | +77.77pp |
| 2011-03-31 | 0.00% | ₹25.00K | ₹1.61 Billion | -- |